Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer

Dateline City:

WHITEHOUSE STATION, N.J. & LONDON

WHITEHOUSE STATION, N.J. & LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
and AstraZeneca (NYSE: AZN) today announced a worldwide licensing
agreement for Merck’s oral small molecule inhibitor of WEE1 kinase
(MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical
studies in combination with standard-of-care therapies for the treatment
of patients with certain types of ovarian cancer.

Language:

English

Contact:

MerckMedia:Caroline Lappetito, [phone]orInvestor:Carol Ferguson, [phone]Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - September 11, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news